ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Study Protocol

Preserving the endothelial glycocalyx in patients undergoing cardiopulmonary bypass: a prospective randomised interventional pilot study of lidocaine and doxycycline (LiDEG trial)

[version 1; peer review: 3 approved with reservations, 1 not approved]
* Equal contributors
PUBLISHED 04 Aug 2020
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Background: During major surgery, particularly heart surgery, an element of the lining of blood vessels, known as the endothelial glycocalyx (EG), can be damaged. This can lead to swelling, low oxygen levels, kidney failure and other problems, which delay recovery. There are laboratory studies that show lidocaine (a local anaesthetic) and doxycycline (an antibiotic) may help protect this lining. The study agents are widely available, cheap and safe drugs.
Trial design and objective: This is a phase IV, single centre, prospective, unblinded, randomised, parallel-group trial. The objectives of the trial are to investigate the role of doxycycline and lidocaine as potential agents to reduce EG shedding and correlate with early postoperative outcomes.
Methods: 60 adult patients undergoing heart surgery requiring cardiopulmonary bypass (CPB) will be randomly assigned to one of three groups: doxycycline group (oral doxycycline, 200mg preoperatively); lidocaine group (perioperative intravenous lidocaine, 1.5mg/kg bolus at induction followed by 2mg/kg/hr infusion for the duration of surgery); and control group (standard care). The randomisation will be undertaken using a sealed opaque envelope method. The primary outcome will be the relative difference in the biochemical marker of EG injury, syndecan-1, at different timepoints in the intraoperative and early post-operative period. Secondary endpoints include vasopressor requirements, markers of organ dysfunction (lung, kidney, brain, arrhythmia), coagulation and inflammation.
Discussion: EG injury is ubiquitous in patients undergoing CPB. Maintaining homeostasis of this delicate layer would appear to be a valuable therapeutic target.  To date no agents have been shown to be effective in protecting the EG. Our study agents have shown some promise in the preclinical setting and would represent a novel therapeutic approach should they show a protective effect.
Trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12619000621112 (26th April 2019).

Keywords

Endothelial glycocalyx, lidocaine, doxycycline, cardiopulmonary bypass, anaesthesia

Introduction

Heart surgery is known to have harmful effects on the lining of blood vessels called the “endothelial glycocalyx” (EG)1,2. The EG is a proteoglycan coating on the luminal side of blood vessels, and is made up of a dynamic layer of polysaccharides, the composition of which is balanced under normal physiological conditions by vascular sheer forces and continued biosynthesis. Under normal conditions, the EG provides protection that helps preserve barrier function, modulate inflammation and house anticoagulant factors1. The EG is also important for normal vascular functions, including fluid and protein extravasation, coagulation/haemostasis and microvascular blood flow.

Damage to the EG results in vascular permeability, white blood cell adhesion, changes in coagulation and ultimately organ oedema and dysfunction3, making it a viable causal mechanism for these outcomes noted in post-operative cardiac patients. Supporting this, there is good evidence that the EG is rapidly shed under both inflammatory and ischaemic conditions4. Rehm and colleagues also detected a component of the EG, syndecan-1, in the plasma of patients undergoing procedures requiring local systemic ischemia, including total circulatory arrest and aortic cross clamping, which indicates that shedding has occurred5. Strategies to protect the EG are thus a viable clinical target in order to reduce adverse outcomes. Currently no measures are taken in routine practice specifically to protect the EG.

One potential strategy is the use of doxycycline, a broad-spectrum matrix metalloprotease inhibitor that reduces metalloprotease activity known to be involved in the EG shedding process4. Research trials have demonstrated that administration of doxycycline reduces EG shedding in rat mesentery vasculature4.

Alternatively, lidocaine is an amide local anaesthetic that has a broad range of applications, including as part of adenosine/lidocaine/magnesium (ALM), a cardiac protective agent. As a combination, ALM is implicated in maintaining endothelium function and vascular permeability and leads to the restoration of EG after shedding6. The primary mechanism within ALM is not yet known, however lidocaine alone has been shown to improve coagulopathies, have vasoactive effects, be a free radical scavenger and have anti-inflammatory properties and is a coronary vasodilator6. Therefore, it is suspected that lidocaine alone may be responsible for the EG-related effects of ALM. In a porcine study, an intraoperative lidocaine infusion significantly reduced the shedding of the EG in a lung transplant model7.

This research trial aims to investigate EG shedding as a cause of adverse outcomes and evaluate the use of both doxycycline and lidocaine as agents to reduce EG shedding and thereby improve early postoperative outcomes.

Objectives

  • 1. To evaluate the EG shedding in plasma and coronary sinus effluent at key time points in cardiopulmonary bypass surgery.

  • 2. To evaluate the relative reduction in EG shedding with doxycycline and lidocaine as individual agents.

  • 3. To correlate any reduction in EG shedding to early postoperative clinical outcomes.

We hypothesize that doxycycline and/ or lidocaine will reduce endothelial glycocalyx shedding in patients during cardiopulmonary bypass surgery.

Protocol

This is protocol version 2.2.

Design

This trial is a phase IV, single centre, prospective, unblinded, randomised, parallel-group trial consisting of three equal treatment arms (1:1:1): control group, doxycycline group, and lidocaine group. There will be 20 patients in each arm.

Study setting

This is a single centre pilot trial that will take place at the Fiona Stanley Hospital (FSH; Perth, WA, Australia), which is a large academic hospital.

Eligibility criteria

All patients undergoing cardiopulmonary bypass at Fiona Stanley Hospital who are ≥18 years old and provide written informed consent will be eligible to participate in the trial.

Patients will be excluded for the following reasons: patient refusal, allergy to trial drug(s), undergoing heart and lung transplant, doxycycline and/or lidocaine contraindicated in patient management, and history of chronic alcohol abuse.

Patients will be recruited via medical personnel in cardiothoracic and anaesthetic clinics and on the ward when applicable.

Written informed consent will be obtained at recruitment (Extended data8). This consent will be obtained by trained research nurses, anaesthetists or cardiothoracic surgery staff. Information sheets and consent forms will only be available in English.

Participants are able to withdraw at any stage of the trial. Samples specifically collected for the trial will be removed and disposed of if requested by the patient. Samples will not be entered to a biorepository.

Outside of initial recruitment, and the possibility of ingesting a single tablet (see Intervention section), participant responsibilities are minimal, and retention should therefore be high with recruited patients.

Outcomes

The primary outcome is the relative difference in the biochemical marker of EG injury, syndecan-1, at different timepoints in the intraoperative and early post-operative period.

Secondary outcomes include:

  • Vasopressor/inotropic requirements: requirement and agent when leaving theatre (low cut off threshold of 5mcg/minute Noradrenaline); requirement at 6 hours into ICU stay

  • Markers of organ function: kidney – Δ creatinine, (Including subgroup analysis for pre-existing renal failure and might need to subgroup into existing and not pre-existing renal failure, requirement of RRT); oxygen requirement – PaO2/FiO2 ratio.

  • Inflammation: white cell count, c-reactive protein, cytokine levels (including tumour necrosis factor α and interleukin (IL)-2, IL-4, IL-6, IL-10, and IL-17 and interferon-γ)

  • Bleeding: blood products usage, ROTEM, prolonged coagulopathy

  • Patient-based: length of ICU stay and pain severity

  • Unplanned return to theatre

  • Postoperative delirium

  • Arrhythmia (presence or absence of atrial fibrillation at 30 days)

Sample size

We plan to recruit 60 patients randomised into three groups of 20 (see Figure 1). All recruits will be at FSH. It is difficult to do accurate power calculations as this is an exploratory pilot study, but using non-interventional human data and a published pig model2,7, with data only available for lidocaine, syndecan-1 levels peak at the end of surgery with a mean of approx. 50 pg/mL (but widely distributed), a pig model showed levels reduced by over 50% with lidocaine exposure. Therefore, if we take a mean of 50, with a standard deviation of 25 and anticipate a reduction by 50%, alpha error 0.05 and power of 80%, we require 16 in each group. Since these are very crude figures, we hope to enrol 20 patients per group to increase our chance of seeing meaningful data.

966ff0de-1fa3-4d92-a40a-350faa672261_figure1.gif

Figure 1. Flow diagram for participant recruitment and treatment.

Previous experience in our department shows a recruitment rate to any clinical trial at approx. 20% of all eligible patients.

Randomization and blinding

This trial aims to recruit 60 patients. Patients will be screened for eligibility in the preoperative clinic or inpatients seen on the ward. Informed consent will be sought from eligible patients. This will be undertaken by anaesthetic staff or research nursing staff. No additional visits will be required by the participants. Participants will be randomised via blocked number draw and assigned to one arm of the study. Patients will undergo randomisation in groups of three, i.e. at the time of recruitment each patient will be randomised to one of the three trial arms with the process repeating with each subsequent three patients. Randomisation will be conducted by opaque envelope method in a 1:1:1 ratio. The envelopes will be sequentially numbered, and each patient will be assigned to the next envelope. The sequencing will be performed externally to the investigators by the hospital pharmacy (clinical trials) unit.

Clinicians and researchers will not be blinded to allocations; however, laboratory staff will not be aware of the allocations and statistical analysis will be performed on the data by researchers on anonymised data blinded to the allocations. Emergency unblinding therefore will not be an issue.

Intervention

Drugs will be supplied by the South Metropolitan Service Pharmacy Department. All treatments will take place in FSH perioperative department. Treatment conditions will be as follows:

  • 1. Doxycycline group: preoperative doxycycline 200mg to be administered at least two hours before patients go to theatre; in addition, patients are to be sitting upright when taking a doxycycline tablet with appropriate amount of water.

  • 2. Lidocaine group: perioperative lidocaine infusion (1.5 mg/kg bolus given at induction of anaesthesia followed by 2 mg/kg/hr infusion until leaving the operating theatre).

  • 3. Control group: standard care

The doxycycline group will be administered their treatment in the ward by ward nursing staff. The lidocaine group will be administered by the attending anaesthetist using the BD Alaris PK syringe pump (CareFusion, Switzerland) using a preprogramed protocol of 1.5mg/kg bolus delivered over five minutes followed by 2mg/kg/hr. Outside of the study drugs, concomitant care will be at the discretion of the primary anaesthetist. This is highly standardised in FSH; all patients receive high dose fentanyl, propofol and vecuronium at induction, and blood pressure support with noradrenaline and glyceryl trinitrate. Dobutamine is the inotrope of choice in FSH. Anaesthesia is maintained using sevoflurane and is titrated to Bispectral Index. Patients are anticoagulated with heparin with target activated clotting time of 400 seconds or greater for the duration of cardiopulmonary bypass and reversed with a suitable dose of protamine. All patients receive 2 grams of tranexamic acid at induction.

Data collection

Trial specific blood samples will be collected intra-operatively and post operation (Table 1).

Table 1. Sample collection time points and measures taken at each time point.

T1T2T3T4T5T6
Induction (pre-
operative bloods)
Pre cross
clamp
3 min post
cross clamp
Post
protamine
ICU
arrival
ICU
White cell count
Haemoglobin
Creatinine
Troponin
Syndecan-1 &
cytokines associated
with EG injury
PlasmaCoronary sinus
&
Plasma
Coronary sinus
&
Plasma
PlasmaPlasmaPlasma
ROTEM

Blood samples will be collected for processing of plasma and storage for batch analysis by specifically appointed trial staff in anaesthesia and ICU. All samples, with the exception of syndecan-1 will be obtained from the existing hospital computer systems as appropriate. Syndecan- 1 and cytokines associated with EG injury will be quantified by ELISA using commercially available kits. ROTEM after protamine will be performed for all patients.

All other data will be extracted from the electronic medical record including ICU records. Telephone contact will be established with the participants if required.

Assessment of safety and adherence

A Data Safety Monitoring Board (DSMB) has been set up specifically for this trial. It consists of a multidisciplinary group to review, at regular intervals, accumulating trial data, in order to monitor the progress of this clinical trial. Their role is to provide advice on safety and/or trial conduct issues by making recommendations to the investigators, on whether to continue, modify or stop this trial for safety or ethical reasons. The DSMB consists of three suitable members with no vested interest into the outcome of this trial who have relevant scientific and medical expertise.

Doxycycline and lidocaine are widely available and are used frequently in the both the community and hospital setting with a well-established therapeutic and safety profile. Furthermore, lidocaine is used often in the setting of cardiac surgery for its class 1b antiarrhythmic and analgesic properties.

Any suspected adverse effects, including allergic reactions, due to the study drugs will be reported as an adverse event and investigated appropriately.

Both the actual and potential risk to patients from both agents used in this trial is considered intermediate.

Clinicians administering treatments and taking samples will be given an education session and supervised by investigators initially.

Data analysis and management

Data analysis. Data will be analysed using GraphPad statistical software version 8.4.2 (Prism Software, San Diego, USA).

We will perform interim analysis after four patients from each group (i.e. 12 patients) and at the halfway point (30 patients) and re look at power analysis if indicated by any early signals or lack of. Patients will be randomised by block number draw whereby participants are randomly assigned to one of the three trial arms in 20 rounds of three, so as to ensure balance across conditions and effective interim analysis. We will perform per protocol and intention to treat analysis on the data. Given the nature of the clinician delivered interventions, we anticipate that very few patients will crossover or be lost to follow-up, therefore the analyses should line up closely.

The principal investigators have a strong working knowledge of medical statistics; however appropriate statistical specialist input will be sought and utilised for this study. Prior studies have shown non normal distribution of syndecan-1 level distribution between participants required logarithmic transformation to use parametric testing2. We will we therefore scrutinise the data using the D’Agostino & Pearson Omnibus test and suitable parametric or non-parametric statistical tests will be used on the data. Results will be expressed accordingly.

Continuous variables and binary data will be scrutinised using appropriate tests, i.e. chi-squared test for binary outcomes, and Student’s T-test for continuous outcomes.

Data management. Information will be stored and analysed on password protected hospital computers at FSH for 15 years. Participants will be anonymised. Demographics, type of surgery etc. and treatment arm will be recorded with the recorded results. All data will be included if possible. Any missing or excluded data will be clearly outlined and explained in resulting manuscript.

All principal investigators will have access to cleaned data sets.

Monitoring

The principal investigators, will permit trial-related monitoring, audits, and regulatory inspections, providing direct access to source data/documents. This may include, but not limited to, the DSMB, review by external sponsors, Human Research Ethics Committees and institutional governance review bodies.

Formal systematic auditing and monitoring will be undertaken by the authors under the supervision of the DSMB at regular time points (i.e. after 12 & 30 participants and at the end of the data collection). This study will be undertaken by experienced researchers. If there is evidence of harm at any timepoint the trial will be suspended and investigated by the DSMB and may be prematurely terminated at any timepoint. Being a pilot, the trial will not be analysed for futility at the interim stages.

The principal investigators state that the trial will be conducted in compliance with the protocol, Good Clinical Practice and the application regulatory requirements. Researchers will regularly liaise with clinicians to further ensure protocol adherence.

Data will be systematically collected by experienced researchers. Of note, there is no financial incentive (or any other form of incentive) for the results to show superiority or non-inferiority in this pilot study.

Ethical considerations

This project has been reviewed and approved by the health research ethics committee (HREC) of the South Metropolitan Health Service, Western Australia (ref RGS-1190). No atypical ethical or consent issues are associated with this pilot study. Participant Information and Consent Forms will be provided to all participants and are available as Extended data8.

Any modifications with a significant impact on the study conduct, patient safety, design, sample size will require a formal protocol amendment. Significant changes considered necessary by principal investigators will require approval from South Metropolitan HREC and relevant health authorities before being instigated. Administrative changes and minor corrections deemed necessary by the principal investigators will be documented and the HREC notified.

Patients enrolled in the trial are covered by FSH hospital indemnity. Due to the short duration of the intervention and the pharmacokinetics of the study agents, post-trial care is not predicted to deviate from standard of care but will be covered by FSH indemnity if required.

Dissemination

It is intended that the results of this pilot study will be published and disseminated in an international journal. A minimum time will be taken to compile results after recruitment of the final participant. Deidentified data will be accessible with the final manuscript.

Study status

The trial started on 1st May 2020 and is currently recruiting patients. The trial is anticipated to finish on the 31st January 2021.

Data availability

Underlying data

No data are associated with this article.

Extended data

Open Science Framework: LiDEG, https://doi.org/10.17605/OSF.IO/Y2F8C8.

This project contains the following extended data:

  • - Informed consent form

Reporting guidelines

Open Science Framework: SPIRIT checklist for ‘Preserving the endothelial glycocalyx in patients undergoing cardiopulmonary bypass: a prospective randomised interventional pilot study of lidocaine and doxycycline (LiDEG trial)’, https://doi.org/10.17605/OSF.IO/Y2F8C8.

Data are available under the terms of the http://creativecommons.org/publicdomain/zero/1.0/ (CC0 1.0 Public domain dedication).

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 04 Aug 2020
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Pannekoek A, Johnson M, Buggy D and Pavey W. Preserving the endothelial glycocalyx in patients undergoing cardiopulmonary bypass: a prospective randomised interventional pilot study of lidocaine and doxycycline (LiDEG trial) [version 1; peer review: 3 approved with reservations, 1 not approved]. F1000Research 2020, 9:894 (https://doi.org/10.12688/f1000research.24485.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 04 Aug 2020
Views
4
Cite
Reviewer Report 02 Feb 2021
David M Baron, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Vienna, Austria 
Approved with Reservations
VIEWS 4
In the submitted study protocol, the authors describe their plan to conduct an unblinded, randomized trial to explore the effects of lidocaine and doxycycline on preserving the integrity of the endothelial glycocalyx in patients undergoing surgery requiring cardiopulmonary bypass. The ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Baron DM. Reviewer Report For: Preserving the endothelial glycocalyx in patients undergoing cardiopulmonary bypass: a prospective randomised interventional pilot study of lidocaine and doxycycline (LiDEG trial) [version 1; peer review: 3 approved with reservations, 1 not approved]. F1000Research 2020, 9:894 (https://doi.org/10.5256/f1000research.27010.r76734)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
6
Cite
Reviewer Report 25 Jan 2021
Jong Wook Song, Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, South Korea 
Approved with Reservations
VIEWS 6
This trial aims to investigate the effect of lidocaine and doxycycline on reduction of EG shedding in cardiac surgery.
  1. In my opinion, assumptions for the sample size calculation seems to be too optimistic. As the authors
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Song JW. Reviewer Report For: Preserving the endothelial glycocalyx in patients undergoing cardiopulmonary bypass: a prospective randomised interventional pilot study of lidocaine and doxycycline (LiDEG trial) [version 1; peer review: 3 approved with reservations, 1 not approved]. F1000Research 2020, 9:894 (https://doi.org/10.5256/f1000research.27010.r76731)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
10
Cite
Reviewer Report 18 Jan 2021
Antonio Nenna, Department of Cardiovascular Surgery, Universita Campus Bio-Medico di Roma, Rome, Italy 
Not Approved
VIEWS 10
Sample size calculation should be verified after ad-interim analysis. Current sample size, considering the published details of the manuscript, seems low.

Details of the primary and secondary endpoints (i.e. definitions of endpoints) should be required. Fold-increase rather ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Nenna A. Reviewer Report For: Preserving the endothelial glycocalyx in patients undergoing cardiopulmonary bypass: a prospective randomised interventional pilot study of lidocaine and doxycycline (LiDEG trial) [version 1; peer review: 3 approved with reservations, 1 not approved]. F1000Research 2020, 9:894 (https://doi.org/10.5256/f1000research.27010.r76732)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
20
Cite
Reviewer Report 05 Aug 2020
Eero Pesonen, Department of Anesthesiology and Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland 
Approved with Reservations
VIEWS 20
Main Considerations

The aim of the intended RCT is to investigate the efficacy of p.o. doxycycline and i.v. lidocaine in reducing endothelial degradation (measured as plasma syndecan-1) in heart surgery with CPB. The focus of the RCT ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Pesonen E. Reviewer Report For: Preserving the endothelial glycocalyx in patients undergoing cardiopulmonary bypass: a prospective randomised interventional pilot study of lidocaine and doxycycline (LiDEG trial) [version 1; peer review: 3 approved with reservations, 1 not approved]. F1000Research 2020, 9:894 (https://doi.org/10.5256/f1000research.27010.r68613)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 04 Aug 2020
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.